<DOC>
	<DOCNO>NCT01636947</DOCNO>
	<brief_summary>This efficacy safety study compare aprepitant ondansetron prevention nausea vomit first cycle moderately emetogenic chemotherapy ( MEC ) participant solid tumor . MECs include number commonly use cancer chemotherapeutic drug include : oxaliplatin-based , irinotecan-based , carboplatin-based regimen . The primary hypothesis study Aprepitant Regimen superior Control ( ondansetron ) Regimen respect percentage participants No Vomiting Overall ( 120 hour follow initiation MEC ) participant solid tumor .</brief_summary>
	<brief_title>A Korean Study Efficacy Safety Aprepitant-based Triple Regimen Prevention Chemotherapy-Induced Nausea Vomiting First Cycle Moderately Emetogenic Chemotherapy ( Non-doxorubicin Hydrochloride Adriamycin Cyclophosphamide Regimens ) ( MK-0869-225 ) ( KMEC )</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Metoclopramide</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Alizapride</mesh_term>
	<mesh_term>Dolasetron</mesh_term>
	<mesh_term>Tropisetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Emetics</mesh_term>
	<criteria>Histologically cytologically confirm malignant disease Scheduled receive single dose one moderately emetogenic chemotherapeutic agent Cycle 1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Karnofsky score ≥60 Predicted life span ≥4 month Laboratory value demonstrate adequate hematologic status Premenopausal females must pregnant lactating must agree use effective birth control Received chemotherapy within 6 month prior start study drug Scheduled receive subsequent treatment due refractory response first second line chemotherapy Received investigational drug within 30 day prior start study drug Radiation therapy abdomen pelvis week prior start study drug Vomiting 24 hour prior start study drug Active infection ( e.g. , pneumonia ) uncontrolled disease ( e.g. , diabetic ketoacidosis , gastrointestinal obstruction ) except malignancy Known hypersensitivity Aprepitant ( EMEND® ) , Dexamethasone 5HT3 receptor antagonist Presentation gastrointestinal obstruction symptom Symptomatic primary metastatic central nervous system malignancy</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>chemotherapy</keyword>
	<keyword>nausea</keyword>
	<keyword>vomit</keyword>
	<keyword>emetogenic</keyword>
	<keyword>cancer</keyword>
	<keyword>antiemetic</keyword>
	<keyword>tumor</keyword>
</DOC>